// App-Quantinova.ai

: 15-Days Duration of Venetoclax Combined with Azacitidine in the Treatment of Relapsed/Refractory High-Risk Myelodysplastic Syndromes: A Retrospective Single-Center Study

Researchers

Presenter

  • Hongyan Tong

Principal Investigators

  • Chen Mei

  • Yanling Ren

  • Xinping Zhou

  • Yingwan Luo

  • Jie Jin

Medical Centers

  • Zhejiang University Cancer Center, Hangzhou, China

  • Department of Hematology, The First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China

  • Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

  • Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, China

  • Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelodysplastic Syndrome

Biomarkers

  • Hormone receptor

Drug/Treatment

  • Vidaza

  • Azacitidine

  • Venetoclax

  • Allopurinol

Outcome

  • N/A

Study Design

  • Efficacy

  • Prospective

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved